Immutep Quarterly Activities Report Q2 FY25
Provided By GlobeNewswire
Last update: Jan 31, 2025
Media Release
SYDNEY, AUSTRALIA, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, provides an update on its activities for the quarter ended 31 December 2024 (Q2 FY25).
Read more at globenewswire.com
